Navigation Links
AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance
Date:3/20/2008

GREENVILLE, S.C., March 20 /PRNewswire-FirstCall/ -- On January 7, 2008, Signalife received a deficiency letter from the American Stock Exchange ("AMEX") pursuant to which it advised that Signalife would need to comply with the $6 million stockholders' equity threshold required for continued listing under AMEX Rules 1003(a)(iii). This notification was triggered by the decline of Signalife's market capitalization to less than $50 million, which previously exempted Signalife from meeting the minimum stockholders' equity requirement. Pursuant to the letter, Signalife submitted to AMEX for its review and acceptance a plan to bring the company into compliance with the aforesaid stockholders' equity requirement. On March 20, 2008, AMEX notified Signalife that it accepted the company's plan of compliance and granted the company an extension until May 7, 2009 to regain compliance with the aforesaid stockholders' equity requirement. Signalife will be subject to periodic review by AMEX Staff during this extension period. Failure to make progress consistent with the plan or to otherwise regain compliance with the aforesaid stockholders' equity requirement by the end of the extension period could result in the company being delisted from AMEX.

About Signalife, Inc.

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife, Inc. is the recipient of the Frost & Sullivan Technological Innovation Award for 2006 and 2008.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. For example, no assurance can be given that Signalife will attain the results set forth in the plan or otherwise satisfy AMEX's continued listing requirements, or that Signalife's common stock will continue to trade on AMEX. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
2. Signalife Provides Corporate Update
3. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
4. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
5. Signalife Achieves $1.98 Million Sales Orders Thus Far
6. Signalife Receives Another $3.3 Million Sales Orders
7. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
8. Signalife Continues to Procure Purchase Orders, Revenues
9. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
10. U.S. Patent 7,299,083 Awarded to Signalife
11. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or ... Data and Safety Monitoring Board (DSMB) for the ... disease (CVD) patients has completed a second planned ... continue as planned without any modifications. The DSMB ... safety or efficacy concerns were identified. The DSMB ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... report "DNA Sequencing - Technologies, Markets and Companies" ... ... report briefly reviews basics of human genome variations, development of ... are described as well as companies developing them. Various applications ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... studies. A microbiome impact grant award has been made to Dr. Renato Polimanti ... smoking and drinking on the oral microbiome. Grant proposals have been vetted by ...
(Date:12/2/2016)... ... December 02, 2016 , ... In ... cervical and lumbar disc production, company President, Jake Lubinski will be traveling to ... the AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:11/30/2016)... Poland , Nov. 30, 2016 Not many of us realize that ... aspects of recovery so we need to do it well. Inadequate sleep levels have ... high blood pressure, stroke, diabetes, and even cancer. Maybe now is the ... present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):